CORRECTION article

Front. Pharmacol., 08 August 2025

Sec. Pharmacogenetics and Pharmacogenomics

Volume 16 - 2025 | https://doi.org/10.3389/fphar.2025.1660169

Correction: Overexpression of Nrf2 in bone marrow mesenchymal stem cells promotes B-cell acute lymphoblastic leukemia cells invasion and extramedullary organ infiltration through stimulation of the SDF-1/CXCR4 axis

    LZ

    Lin Zheng 1,2,3

    CP

    Chengyun Pan 1,3

    DM

    Dan Ma 1,3,4

    QS

    Qin Shang 1,3

    TH

    Tianzhen Hu 1,3

    TZ

    Tianzhuo Zhang 1,3

    QK

    Qian Kang 1,3

    XH

    Xiuying Hu 1,3

    SC

    Shuyun Cao 1,3

    LW

    Li Wang 1,2,3

    HL

    Hong Luo 1,2,3

    JW

    Jishi Wang 1,2,3*

  • 1. Department of Hematology, Affiliated Hospital of Guizhou Medical University, Guiyang, China

  • 2. Department of Clinical Medical School, Guizhou Medical University, Guiyang, China

  • 3. Department of Guizhou Province Hematopoietic Stem Cell Transplantation Center and Key Laboratory of Hematological Disease Diagnostic and Treatment Centre, Guiyang, China

  • 4. Guizhou Provincial Engineering Technology Research Center for Chemical Drug R&D, Guizhou Medical University, Guiyang, China

Article metrics

View details

882

Views

187

Downloads

In the published article, there was an error in Figures 2A, C, Figures 3N, O, Figures 5A, C, as published. The error was caused by an image misalignment during image selection of raw data. The corrected Figures 2A, C, Figures 3N, O, Figures 5A, C and their captions appear below.

FIGURE 2

Cell migration and invasion assays are displayed for RS4:11 and Nalm6 cells. Panels A-C show images of migration and invasion with different treatments. Graphs D-G quantify cell counts, highlighting significant differences with statistical markers.

Nrf2 in BMSCs promotes B-ALL cell migration and invasion (A) Transwell assays performed for analyzing cell invasion and migration after incubation with Nalm-6/RS4; 11 alone and co-culture with MSCs for 24 h (B, D, E) Downregulation of Nrf2 expression in MSCs was tested for migration and invasion rates of Nalm6/RS4:11 cells in the microcellular compartment at 24 h. Migration and invasion rates were significantly decreased in the downregulated group (p < 0.01). (C,F,G) Upregulation of Nrf2 expression in MSCs revealed a significant increase in the migration and invasion rate of Nalm6/RS4: 11 in cells within the upregulated group at 24 h. Each assay was conducted thrice independently and denoted as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001.

FIGURE 3

Panels N to Q show cell migration and invasion assays with Nalm6 and RS4:11 cells, using treatments with AMD3100 and Nrf2 variants. Bar graphs illustrate quantitative results, indicating significant differences in cell counts between untreated and treated groups, with comparisons between MSCs-EV and MSCs-SI-Nrf2 or MSCs-LV-Nrf2. Statistical significance is denoted by asterisks, and "ns" indicates not significant.

CXCR4 overexpression in B-ALL cells was positively related to Nrf2 (A) GEPIA database analysis for CXCR4 levels within tumor and non-carcinoma tissues. (B) RT-PCR assay on CXCR4 levels within healthy (n = 10), complete remission (n = 20) and relapsed (n = 20) B-ALL patients. (C,D,E,F) Western blotting was conducted for detecting CXCR4 and Nrf2 protein levels among healthy (n = 4), complete remission (n = 6) and relapsed B-ALL patient (n = 8) samples. (G) Association of Nrf2 with CXCR4 in B-ALL was measured through RT-PCR (n = 20, r = 0.7275 = 0.5232, p = 0.0003). (H,I) Western blotting was performed to detect the expression of CXCR4 in RS4; 11/Nalm-6 in the co-culture system after downregulation of Nrf2 in MSCs. (J,K) Western blotting was performed to detect the expression of CXCR4 in RS4; 11/Nalm-6 in the co-culture system after upregulation of Nrf2 in MSCs. (L) MSCs-SI-Nrf2 significantly affected leukemia cell sensitivity to vincristine. (M) MSCs-LV-Nrf2 had a similarly significant change in changing leukemia cell sensitivity to vincristine. (N–Q) Transwell tests were performed to detect the number of Nalm-6 and RS4; 11 cells migrating and invading in the MSCs-EV, MSCs-SI-Nrf2, MSCs-LV-Nrf2, and treated AMD3100 (20 μM, upper chamber) groups, respectively, after 24 h of cell incubation. Each assay was conducted thrice independently and denoted as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001.

FIGURE 5

Western blot and bar graph data examine protein expression and cell migration/invasion in leukemia cell lines RS4:11 and Nalm6. Panel A shows protein expression levels of CXCR4, P-AKT, AKT, P-ERK, ERK, and β-Actin across different conditions. Panels B and C display migration and invasion assays under treatments with MK2206 and PD98059 inhibitors, respectively, accompanied by bar graphs indicating significant differences between experimental groups.

PI3K/AKT and ERK pathway activation mediated by Nrf2 overexpression in MSCs made a vital impact on B-ALL cell invasion and migration. (A) PI3K/AKT and ERK pathway in MSCs-LV-Nrf2 and RS4; 11/Nalm-6 co-culture conditions was evaluated through Western blotting. Histogram showed protein level quantification. (B) Addition of AKT inhibitor (MK2206), the results showed that the migration and invasion ability of leukemia cells were attenuated, and there was no statistically significant difference between the EV and LV-Nrf2 groups. (C) Addition of ERK inhibitor (PD98059) to the upper compartment also significantly blocked the migration and invasion ability of leukemia cells, with no statistically significant difference between the EV and LV-Nrf2 groups. Each assay was conducted thrice independently and represented by average soil SD. *p < 0.05, **p < 0.01, ***p < 0.001.

The original version of this article has been updated.

Statements

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

B-acute lymphocytic leukemia, MSCs, Nrf2, SDF-1/CXCR4, extramedullary infiltration

Citation

Zheng L, Pan C, Ma D, Shang Q, Hu T, Zhang T, Kang Q, Hu X, Cao S, Wang L, Luo H and Wang J (2025) Correction: Overexpression of Nrf2 in bone marrow mesenchymal stem cells promotes B-cell acute lymphoblastic leukemia cells invasion and extramedullary organ infiltration through stimulation of the SDF-1/CXCR4 axis. Front. Pharmacol. 16:1660169. doi: 10.3389/fphar.2025.1660169

Received

05 July 2025

Accepted

25 July 2025

Published

08 August 2025

Volume

16 - 2025

Edited and reviewed by

Pier Paolo Piccaluga, University of Bologna, Italy

Updates

Copyright

*Correspondence: Jishi Wang,

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics